Carlisle Companies (CSL)
(Delayed Data from NYSE)
$375.30 USD
-4.03 (-1.06%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $375.41 +0.11 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
CSL 375.30 -4.03(-1.06%)
Will CSL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CSL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CSL
GE Aerospace (GE) Q1 Earnings Surpass Estimates, Up Y/Y
Danaher (DHR) Q1 Earnings Beat, Biotechnology Sales Dip Y/Y
CSL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate LSB (LXU) to Report a Decline in Earnings: What to Look Out for
Insights Into Carlisle (CSL) Q1: Wall Street Projections for Key Metrics
Here's Why Carlisle (CSL) Fell More Than Broader Market
Other News for CSL
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Carlisle Q1 2024 Earnings Preview
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Madison Mid Cap Fund Q1 2024 Investment Strategy Letter
Carlisle SynTec Systems Congratulates Jurin Roofing Services on Winning the 2024 Excellence in Single-Ply Award